Joseph Beaulieu - 09 Aug 2022 Form 4 Insider Report for Epizyme, Inc.

Role
Senior Vice President, Finance and Corporate Controller
Signature
/s/ John Weidenbruch, attorney-in-fact
Issuer symbol
N/A
Transactions as of
09 Aug 2022
Net transactions value
+$27,989
Form type
4
Filing time
11 Aug 2022, 20:53:26 UTC
Previous filing
21 Mar 2022
Next filing
16 Aug 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction EPZM Common Stock, par value $0.0001 Options Exercise $417,000 +300,000 +969% $1.39 330,963 09 Aug 2022 Direct
transaction EPZM Common Stock, par value $0.0001 Tax liability $389,011 -279,864 -85% $1.39 51,099 09 Aug 2022 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction EPZM Stock Option (Right to Buy) Options Exercise $0 -300,000 -100% $0.000000* 0 09 Aug 2022 Common Stock 300,000 $1.39 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These shares were withheld so the Reporting Person could satisfy the exercise price arising from a net (cashless) exercise of stock options that occurred on August 9, 2022.
F2 On June 27, 2022, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement"), by and among the Issuer, Ipsen Pharma SAS and Hibernia Merger Sub, Inc. Pursuant to the terms of the Merger Agreement, each Exercisable Pre-Close Option (as defined in the Merger Agreement) became exercisable on the Acceleration Date (August 5, 2022) up to and through the close of regular trading on the Nasdaq Stock Market on the second (2nd) business day thereafter (August 9, 2022).

Remarks:

Senior Vice President, Finance and Corporate Controller